FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386216377> ?p ?o ?g. }

• W4386216377 abstract "Treatment with the alkylating agent temozolomide is known to be prognostically beneficial in a subset of glioblastoma patients. Response to such chemotherapeutic treatment and the prognostic benefit have been linked to the methylation status of O6-methylguanine-DNA methyltransferase (MGMT). To date, it has not been entirely resolved which methylation pattern of MGMT is most relevant to predict response to temozolomide treatment and outcome. In this retrospective study, we compared the methylation patterns, analyzed by Sanger sequencing, of 27 isocitrate dehydrogenase (IDH)-wildtype glioblastoma patients that survived more than 3 years (long-term survivors) with those of 24 patients who survived less than a year after initial surgery (short-term survivors). Random Forest-, Correlation-, and ROC-curve analyses were performed. The data showed that MGMT is typically methylated in long-term survivors, whereas no prominent methylation is observed in short-term survivors. The methylation status of CpGs, especially in the promoter and exon1/enhancer region correlated highly with outcome. In addition, age and temozolomide treatment were strongly associated with overall survival. Some CpGs in the enhancer region, in particular CpG 86 (bp + 154), demonstrated high values associated with overall survival in the Random Forest analysis. Our data confirm previously published prognostic factors in IDH-wildtype glioblastoma patients, including age and temozolomide treatment as well as the global MGMT methylation status. The area frequently used for decision making to administer temozolomide at the end of exon1 of MGMT, was associated with outcome. However, our data also suggest that the enhancer region, especially CpG 86 (bp + 154) is of strong prognostic value. Therefore, we propose further investigation of the enhancer region in a large prospective study in order to confirm our findings, which might result in an optimized prediction of survival in glioblastoma patients, likely linked to response to temozolomide treatment." @default.
• W4386216377 created "2023-08-29" @default.
• W4386216377 creator A5000919609 @default.
• W4386216377 creator A5004099362 @default.
• W4386216377 creator A5004898224 @default.
• W4386216377 creator A5014418918 @default.
• W4386216377 creator A5017177249 @default.
• W4386216377 creator A5037811499 @default.
• W4386216377 creator A5045726522 @default.
• W4386216377 creator A5081827829 @default.
• W4386216377 date "2023-08-28" @default.
• W4386216377 modified "2023-10-05" @default.
• W4386216377 title "MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value" @default.
• W4386216377 cites W111616551 @default.
• W4386216377 cites W1965705450 @default.
• W4386216377 cites W1997950881 @default.
• W4386216377 cites W2035021866 @default.
• W4386216377 cites W2079232919 @default.
• W4386216377 cites W2094354684 @default.
• W4386216377 cites W2101664201 @default.
• W4386216377 cites W2105100844 @default.
• W4386216377 cites W2106816824 @default.
• W4386216377 cites W2143481518 @default.
• W4386216377 cites W2151794458 @default.
• W4386216377 cites W2159485898 @default.
• W4386216377 cites W2169590480 @default.
• W4386216377 cites W2171418517 @default.
• W4386216377 cites W2288710734 @default.
• W4386216377 cites W2328946792 @default.
• W4386216377 cites W2342351330 @default.
• W4386216377 cites W2366536035 @default.
• W4386216377 cites W2760872013 @default.
• W4386216377 cites W2765287984 @default.
• W4386216377 cites W2885854788 @default.
• W4386216377 cites W2948734763 @default.
• W4386216377 cites W2996790540 @default.
• W4386216377 cites W3110787789 @default.
• W4386216377 cites W3128964921 @default.
• W4386216377 cites W3174246647 @default.
• W4386216377 cites W4311201303 @default.
• W4386216377 cites W4376848386 @default.
• W4386216377 doi "https://doi.org/10.1186/s40478-023-01622-w" @default.
• W4386216377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37641156" @default.
• W4386216377 hasPublicationYear "2023" @default.
• W4386216377 type Work @default.
• W4386216377 citedByCount "0" @default.
• W4386216377 crossrefType "journal-article" @default.
• W4386216377 hasAuthorship W4386216377A5000919609 @default.
• W4386216377 hasAuthorship W4386216377A5004099362 @default.
• W4386216377 hasAuthorship W4386216377A5004898224 @default.
• W4386216377 hasAuthorship W4386216377A5014418918 @default.
• W4386216377 hasAuthorship W4386216377A5017177249 @default.
• W4386216377 hasAuthorship W4386216377A5037811499 @default.
• W4386216377 hasAuthorship W4386216377A5045726522 @default.
• W4386216377 hasAuthorship W4386216377A5081827829 @default.
• W4386216377 hasBestOaLocation W43862163771 @default.
• W4386216377 hasConcept C104317684 @default.
• W4386216377 hasConcept C111936080 @default.
• W4386216377 hasConcept C126322002 @default.
• W4386216377 hasConcept C140173407 @default.
• W4386216377 hasConcept C143998085 @default.
• W4386216377 hasConcept C150194340 @default.
• W4386216377 hasConcept C190727270 @default.
• W4386216377 hasConcept C2776194525 @default.
• W4386216377 hasConcept C2777389519 @default.
• W4386216377 hasConcept C2779527866 @default.
• W4386216377 hasConcept C33288867 @default.
• W4386216377 hasConcept C502942594 @default.
• W4386216377 hasConcept C54355233 @default.
• W4386216377 hasConcept C71924100 @default.
• W4386216377 hasConcept C86803240 @default.
• W4386216377 hasConcept C91965660 @default.
• W4386216377 hasConceptScore W4386216377C104317684 @default.
• W4386216377 hasConceptScore W4386216377C111936080 @default.
• W4386216377 hasConceptScore W4386216377C126322002 @default.
• W4386216377 hasConceptScore W4386216377C140173407 @default.
• W4386216377 hasConceptScore W4386216377C143998085 @default.
• W4386216377 hasConceptScore W4386216377C150194340 @default.
• W4386216377 hasConceptScore W4386216377C190727270 @default.
• W4386216377 hasConceptScore W4386216377C2776194525 @default.
• W4386216377 hasConceptScore W4386216377C2777389519 @default.
• W4386216377 hasConceptScore W4386216377C2779527866 @default.
• W4386216377 hasConceptScore W4386216377C33288867 @default.
• W4386216377 hasConceptScore W4386216377C502942594 @default.
• W4386216377 hasConceptScore W4386216377C54355233 @default.
• W4386216377 hasConceptScore W4386216377C71924100 @default.
• W4386216377 hasConceptScore W4386216377C86803240 @default.
• W4386216377 hasConceptScore W4386216377C91965660 @default.
• W4386216377 hasFunder F4320323260 @default.
• W4386216377 hasFunder F4320325738 @default.
• W4386216377 hasIssue "1" @default.
• W4386216377 hasLocation W43862163771 @default.
• W4386216377 hasLocation W43862163772 @default.
• W4386216377 hasOpenAccess W4386216377 @default.
• W4386216377 hasPrimaryLocation W43862163771 @default.
• W4386216377 hasRelatedWork W1965705450 @default.
• W4386216377 hasRelatedWork W1991000956 @default.
• W4386216377 hasRelatedWork W1995740954 @default.
• W4386216377 hasRelatedWork W2057934195 @default.
• W4386216377 hasRelatedWork W2113742699 @default.

• next